Japanese-specific CP-673451 molecular weight costs, health utilities and disease transition rates were used. Sustained viro-logic response rates at 24 weeks (SVR24) for DCV+ASV were 79.5 %in NRs and PRs and 87 %in IFN-ineligible patients. SVR24 rates for TVR+pegIFNa/RBV and SMV+pegIFNa/RBV were 42.8 %and 57.6%, respectively, for both NRs and PRs. Results The table reports total expected HCV related costs and QALE driven by changes in SVR stratified by treatment scenario

and cohort age. Conclusion Treatment options are limited for patients who have previously failed to achieve SVR with IFN-based therapy or who are IFN-ineligible. The superior levels of SVR associated with DCV+ASV are associated with significant savings in projected disease costs and increased QALE,

even in those of more advanced age. Total HCV Lifetime Costs* *Excluding cost of HCV therapy Disclosures: Philip McEwan – Consulting: Bristol-Myers Squibb Yong Yuan – Employment: Bristol Myers Squibb Company Anupama Kalsekar – Employment: Bristol Myers Squibb Ann C. Tang – Employment: Bristol-Myers Suqibb Hiromitsu Kumada – Speaking and Teaching: Bristol-Myers Squibb,Pharma International, MSD, Dainippon Sumitomo, Tanabe Mitsubishi, Ajinomoto The following Roxadustat molecular weight people have nothing to disclose: Thomas Ward, Isao Kamae, Mariko Kobayashi, Sachie Inoue Introduction The therapy landscape of treatment

for hepatitis C virus (HCV) has evolved considerably in recent years, while the degree of SVR improvement is diminishing between newer treatments and its incremental impacts on economic outcomes are still unknown Given these challenges this study was designed to quantify the expected cost-offset and improvement in health outcomes associated with unit increments in SVR independent of the specific HCV treatment used. Methods A published Markov lifetime model with a payer perspective was used to estimate the reduction in complications costs and increase in quality adjusted life expected (QALE) associated with unit increases (per %point) in SVR. Analysis was stratified into patient groups aged 40, 50, 60 and 70 years across fibro-sis stages F0 through F4. US specific Teicoplanin and previously published disease transition rates, costs of complications (2013 values) and health related utility were utilised with both future costs and benefits discounted at 3%. Results Reported in the table are the expected increase in QALE and decrease in complication-related costs associated with an increase of one SVR %point stratified by age and fibrosis stage: Conclusion Through the presentation of expected costs offsets and health benefits (QALE) associated with a one % point improvement in SVR we enable the value associated with an arbitrary SVR level to be derived.